RT Journal Article
SR Electronic
A1 Nichols, Emma Hitt
T1 Potential Biomarkers for Identification of PML in MS
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 29
SP 21
OP 22
DO 10.1177/155989771429018
UL http://mdc.sagepub.com/content/14/29/21.abstract
AB Although natalizumab has high efficacy in patients with multiple sclerosis (MS), a risk of developing progressive multifocal leukoencephalopathy (PML) has been identified in patients exposed to it. PML is a concerning adverse event of natalizumab, as PML can cause substantial morbidity or mortality in MS patients. This article discusses the management of PML in patients with MS, the prevalence of John Cunningham virus reactivation during treatment with natalizumab, as well as the use of T2*-weighted high-resolution MRI to detect PML